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Concordant peripheral lipidome signatures in two
large clinical studies of Alzheimer’s disease
Kevin Huynh 1,2,28, Wei Ling Florence Lim 3,4,28, Corey Giles1, Kaushala S. Jayawardana1, Agus Salim1,5,6,7,
Natalie A. Mellett1, Adam Alexander T. Smith1, Gavriel Olshansky1, Brian G. Drew1,2,
Pratishtha Chatterjee 3,8,9, Ian Martins 3,4, Simon M. Laws 3,10,11, Ashley I. Bush 12,
Christopher C. Rowe12,13, Victor L. Villemagne13,14, David Ames15, Colin L. Masters12, Matthias Arnold 16,17,
Kwangsik Nho18,19,20, Andrew J. Saykin 18,20,21, Rebecca Baillie 22, Xianlin Han 23,
Rima Kaddurah-Daouk 16,24,25,29 ✉, Ralph N. Martins3,4,8,9,26,27,29 ✉ & Peter J. Meikle 1,2,29 ✉

Changes to lipid metabolism are tightly associated with the onset and pathology of Alzheimer’s
disease (AD). Lipids are complex molecules comprising many isomeric and isobaric species,
necessitating detailed analysis to enable interpretation of biological signiﬁcance. Our expanded
targeted lipidomics platform (569 species across 32 classes) allows for detailed lipid separation
and characterisation. In this study we examined peripheral samples of two cohorts (AIBL, n =
1112 and ADNI, n = 800). We are able to identify concordant peripheral signatures associated
with prevalent AD arising from lipid pathways including; ether lipids, sphingolipids (notably GM3
gangliosides) and lipid classes previously associated with cardiometabolic disease (phosphatidylethanolamine and triglycerides). We subsequently identiﬁed similar lipid signatures in both
cohorts with future disease. Lastly, we developed multivariate lipid models that improved
classiﬁcation and prediction. Our results provide a holistic view between the lipidome and AD
using a comprehensive approach, providing targets for further mechanistic investigation.
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lzheimer’s disease (AD) is a neurodegenerative disease
characterised by progressive decline in cognitive function,
usually presenting with memory loss. In the sporadic form
of AD, symptoms usually begin to manifest after the age of 65,
and with the ageing global population, the number of people with
AD has been estimated to reach 81 million worldwide by 2040
(ref. 1). The failure of many AD clinical trials over recent years
has led to the call for a paradigm shift in AD research. It is now
recognised that additional underlying mechanisms are involved in
the pathogenesis of AD. We seek to provide a deeper molecular
understanding of metabolic pathways implicated in AD to identify key enzymes, transporters and signalling molecules that are
most amenable for therapeutic targeting. As there are no
appropriate sporadic mouse models of AD, human studies are
essential for better understanding pathogenesis of AD. In particular, statistically powered studies are needed to detect the
associations beneath the natural human biological variation.
Lipids are fundamental to every living system. These diverse
and biologically important molecules comprise thousands of
individual species, spanning multiple classes and subclasses. In
plasma, the majority of lipids are small amphiphilic molecules
(including cholesterol) that make up the circulating lipoprotein
particles such as high- and low-density lipoprotein (HDL and
LDL). With recent advances to mass spectrometry and highperformance liquid chromatography, it is now feasible to examine
in detail the comprehensive plasma lipidome in a human population or clinical study2. Quantiﬁcation and characterisation of
these diverse lipid molecules form the foundation of the ﬁeld
known as lipidomics.
Evidence that lipids are involved in AD have been demonstrated via alterations observed in phospholipid3–5, plasmalogens6, ceramide7, ganglioside8 and sulfatide7,9 compositions in
the brain. Several recent studies indicate that altered phospholipid
metabolism associated with AD pathogenesis is also observed in
the blood5,10,11, thus encouraging discovery studies for bloodbased lipid markers. Furthermore, a recent large-scale genomewide association meta-analysis has identiﬁed genes involved in
lipid metabolism as key risk factors for AD12.
The plasma lipidome is complex and consists of many isomeric and isobaric species13, these are species that share similar
or identical elemental composition but might be structurally
different and display speciﬁc associations with biological outcomes. Existing lipidomic studies often employ techniques that
either have limited coverage of the lipidome (e.g., focusing on
one or two lipid classes) and/or provide poor resolution of lipid
species5,14–17. Limited speciﬁcity of lipidomic platforms can
result in the aggregation of multiple species in one signal,
limiting interpretation and reproducibility. Comprehensive
approaches using untargeted lipidomics can provide greater
coverage of the lipidome18,19, but can sometimes result in
ambiguous identiﬁcations. More recent studies into lipidomics
and dementia with updated methodology have shown that
more structural granularity can lead to improved interpretation
of results20. We have recently expanded our lipidomic platform
to better characterise isomeric lipid species, now measuring
569 lipids from 32 classes and subclasses. Our methodology
focuses on lipid and lipid-like compounds utilising chromatographic separation. We have applied this methodology to
two large independent studies: The Australian Imaging,
Biomarkers and Lifestyle (AIBL) ﬂagship study of ageing21 and
the Alzheimer’s Disease Neuroimaging Initiative baseline
(ADNI) cohort. Here we show the importance of capturing the
comprehensive lipidome and highlight the necessity of
obtaining molecular structural detail to identify key lipid
pathways to link the plasma lipidome with AD and the future
onset of AD.
2

Results
Lipidomic analysis of the AIBL and ADNI cohort. Between the
two cohorts, a total of 5733 samples (including quality controls
and blanks) on 1912 unique individuals were analysed. The
characteristics of individuals in the cross-sectional and longitudinal analysis are shown in Table 1 and further breakdowns are
provided in Supplementary Table 1.
We developed our platform to better characterise the lipids in
human plasma22. In total, we are able to examine 32 lipid classes
and subclasses (conditions detailed in Supplementary Table 2) for
both cohorts. In general, a similar correlation structure was
observed within the AIBL and ADNI cohorts between lipid
classes and many clinical measures (Fig. 1). Many commonly
reported lipid species associated with AD, such as sphingolipids
and ether lipids, are often reported with ambiguous annotations,
where the reported species are the sum of several isomers. Here
we report the detailed characterisation of these species.
Sphingolipids are structurally resolved through collisioninduced dissociation (CID), where fragments correspond to the
sphingoid base, with the exception of sphingomyelins. Dissociation of sphingomyelin species under normal conditions results in a
product ions that yields only sum composition data, i.e. the
sphingomyelin species, SM(42:2). To determine sphingomyelin
structural composition, we repeated the mass spectrometry
analysis on pooled plasma samples in the presence of lithium
acetate as described previously22. The lithiated adduct of
sphingomyelins produces product ions corresponding to the
sphingoid base and n-acyl chain (Fig. 1a) allowing for structural
identiﬁcation. Alignment through chromatography highlights that
our measurement of SM(42:2), for example, is chromatographically separated into SM(d18:1/24:1) and SM(d18:2/24:0) (Fig. 1a).
Similarly, this approach was repeated with the different
glycerophospholipid classes to capture isomeric and isobaric
structural details where they were chromatographically resolved.
Examination of the transition m/z 770.6/184.1 corresponding
to the phosphatidylcholine/alkylphosphatidylcholine/alkenylphosphatidylcholine species PC(35:3)/PC(O-36:3)/PC(P-36:2) results
in nine distinct peaks (Fig. 1b). Here we report the complete
separation of diacyl odd-numbered phosphatidylcholine species,
the non-plasmalogen ether lipids PC(O) and the plasmalogen
ether lipids, PC(P). Results were conﬁrmed by exploiting the
susceptibility of plasmalogens to acid hydrolysis (Fig. 1b). The
correlation structure of all 32 classes and subclasses along with
clinical variables is depicted in Fig. 1c.
Concordance of associations between two studies with AD.
After adjustment for covariates (including age, sex, body mass
index (BMI), total cholesterol, HDL-C, triglycerides, site of sample
collection, APOE ε4 alleles, omega-3 supplementation and statin
use). There were 12 and 3 classes signiﬁcantly associated with AD in
the AIBL and ADNI1 cohorts, respectively, after false discovery rate
(FDR) correction (Fig. 2), corresponding to 147 and 87 lipids,
respectively (219 and 157 uncorrected, Fig. 3). Meta-analysis
using a ﬁxed-effects model identiﬁed 197 lipids and 11 classes
associated with AD between both cohorts (Figs. 2 and 3). The
lipid classes associated were predominately from the sphingolipid
classes: dihydroceramides (dhCer), trihexosylceramides (Hex3Cer),
GM3 gangliosides (GM3), GM1 gangliosides (GM1) and ether
lipids classes: alkylphosphatidylcholine [PC(O)], alkenylphosphatidylcholine [PC(P)], alkylphosphatidylethanolamine [PE(O)],
alkenylphosphatidylethanolamine [PE(P)], alkyldiacylglycerol
[TG(O)].
While all plasmalogens (alkenyl classes) are ether lipids, not all
ether lipids are plasmalogens. This distinction is important when
factoring in their biological signiﬁcance. Independent of multiple
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Table 1 Study characteristics.
Prevalent analysis (latest time pointsa)

AIBL

P value

Control

AD

n
Age (years)b
Gender (% female)c
BMI (kg/m2)b
Cholesterol (mmol/l)b
HDL-C (mmol/l)b
Triglycerides (mmol/l)b
Site (%Melbourne)c
ApoE (no. of ε4 alleles)c
0
1
2
Time to conversion/last follow-up (years)
Number of MCI individuals (%)

696
75.27 (6.53)
408 (58.6)
26.29 (4.35)
5.26 (1.12)
1.58 (0.43)
1.26 (0.63)
402 (57.8)

268
81.40 (7.91)
159 (59.3)
25.52 (3.71)
5.39 (1.31)
1.50 (0.41)
1.50 (0.78)
185 (69.0)

523 (75.1)
163 (23.4)
10 (1.4)

99 (36.9)
131 (48.9)
38 (14.2)

ADNI

Prevalent analysis (baseline samples)

n
Age (years)b
Gender (%female)a
BMI (kg/m2)b
Cholesterol (mmol/l)b
HDL-C (mmol/l)b
Triglycerides (mmol/l)b
No. of non-fasting
ApoE (No. ε4 alleles)c
0
1
2
Time to conversion/last follow-up (years)
Number of MCI individuals (%)
aLatest time point utilises
bTwo-group ANOVA.
bChi-square.

2.96 × 10−32
0.899
0.01
0.106
0.008
9.42 × 10−7
0.002
7.31 × 10−33

P value

Control

AD

210
75.78 (4.93)
103 (49.0)
26.76 (4.34)
4.72 (0.94)
1.38 (0.45)
1.43 (0.81)
19 (9.0)

178
75.21 (7.52)
88 (49.4)
25.57 (3.97)
4.77 (0.94)
1.37 (0.44)
1.42 (0.68)
13 (7.3)

154 (73.3)
51 (24.3)
5 (2.4)

60 (33.7)
85 (47.8)
33 (18.5)

0.364
1
0.005
0.611
0.838
0.951
0.662
1.52 × 10−15

Incident AD analysis (baseline samples)
Non-converters

Converters

714
70.30 (6.90)
412 (57.7)
26.46 (4.19)
5.49 (1.06)
1.67 (0.45)
1.31 (0.61)
398 (55.7)

68
77.00 (6.86)
36 (52.9)
24.77 (3.64)
5.50 (1.08)
1.68 (0.51)
1.34 (0.55)
44 (64.7)

516 (72.3)
177 (24.8)
21 (2.9)
6.15 (2.18)
47 (6.5)

25 (36.8)
33 (48.5)
10 (14.7)
3.06 (2.03)
50 (73.5)

P value
5.83 × 10−14
0.529
0.001
0.886
0.853
0.784
0.195
1.02 × 10−10

3.31 × 10−27
2.63 × 10−56

Incident AD analysis (baseline samples)
Non-converters

Converters

397
75.28 (6.34)
164 (41.3)
26.69 (4.20)
4.75 (0.97)
1.36 (0.44)
1.40 (0.84)
34 (8.6)

166
75.09 (7.06)
64 (38.6)
25.69 (4.03)
4.84 (1.09)
1.43 (0.46)
1.36 (0.65)
14 (8.4)

257 (64.7)
118 (29.7)
22 (5.5)
2.76 (0.91)
197 (49.6)

58 (34.9)
83 (50.0)
25 (15.1)
1.67 (0.89)
163 (98.2)

P value
0.754
0.608
0.009
0.331
0.08
0.586
1
1.91 × 10−10

4.19 × 10−34
2.04 × 10−27

the most recent/last available sample for each participant out of all samples acquired for lipidomics.

covariates, the majority of the ether lipid classes were negatively
associated with AD (Figs. 2 and 3a). This effect is compounded
when the ether lipids are esteriﬁed with omega-3 fatty acids, such
as the 22:6 acyl chain (docosahexaenoic acid, DHA). However, it
should be noted that ether lipids with polyunsaturated fatty acids
other than omega-3 were still negatively associated with AD
(Fig. 3b and Supplementary Table 3), highlighting that the effect
is not necessarily driven by omega-3 fatty acids. A nonglycerophospholipid subclass of ether lipids, alkyldiacylglycerols,
TG(O), were negatively associated with AD, despite the species
measured predominately containing saturated or monounsaturated species (Figs. 2 and 3).
Ceramide and sphingomyelin species presented with both
positive and negative associations with AD resulting in no
signiﬁcant associations at the class level. In both cohorts, dhCer
was notability negatively associated with AD. Negative associations were primarily driven by 22:0 and 24:0 saturated species in
the sphingolipid n-acyl moiety, while positive associations were
predominately the shorter 18:0, 20:0 and monounsaturated
24:1 species. The sphingoid base had no apparent inﬂuence on
the association in AD. This sphingolipid pattern in AD is much
weaker in the ADNI1 cohort (Fig. 3 and Supplementary Table 3).
This effect was also seen for other complex sphingolipids,
where a positive association or trend was observed at the class
level (monohexosylceramide, HexCer, dihexosyolceramide, Hex2Cer, Hex3Cer, GM3 and GM1 gangliosides) in both AIBL and

ADNI cohorts (Fig. 2), but individual species within these classes
present with the same opposing relationship (negative association
with the n-acyl chains 22:0 and 24:0, and positive association with
the 18:0, 20:0 and 24:1 species). This combined trend resulted in
no association with 22:0 and 24:0 n-acyl sphingolipids but an
increased association in sphingolipids with n-acyl chains 18:0,
20:0 and 24:1, such as GM3(d18:1/24:1) which has the strongest
positive association with AD (Fig. 3 and Supplementary Table 3).
A notable pattern observed in both AIBL and ADNI cohorts,
even after adjustment for clinical measures of cholesterol and
triglycerides (TGs), was the positive associations of the lipid
classes phosphatidylethanolamine (PE) and TG (Fig. 3). This
effect has been noted in diseases where dyslipidemia is prevalent
such as type 2 diabetes23.
Similar lipids are associated with cross sectional and longitudinal analysis of AD in both cohorts. Using Cox regression
models, we explored lipids associated with the risk of developing
AD in the future. Baseline characteristics of this analysis are
presented in Supplementary Table 1. We noted that in both
cohorts, there was also a higher proportion of individuals with
mild cognitive impairment (MCI) in the conversion group. After
adjustment for covariates (age as time scale, sex, BMI, total
cholesterol, HDL-C, TGs, site of sample collection, APOE ε4
alleles, omega-3 supplementation and statin use), there were
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Q1: m/z 770
Q3: m/z 184
Control
Acid treated

3

Intensity

Intensity

SM(42:2)
SM(d18:1/24:1)
SM(d18:2/24:0)

6

4

7
9

2

5

1) +2 isotope of PC(35:4)
2) PC(35:3) (a)
3) PC(35:3) (b)
4) +1 isotope of SM(39:3)
5) +2 isotope of PC(O-36:4)
6) PC(O-36:3) (a)
7) PC(O-36:3) (b)
8) PC(P-36:2) (a)
9) PC(P-36:2) (b)

8
1

Retention time

c

Retention time

ADNI

 = 0.7

 = –0.7

Dihydroceramide [dhCer]
Ceramide [Cer]
Monohexosylceramide [HexCer]
Dihexosylceramide [Hex2Cer]
Trihexosylceramide [Hex3Cer]
GM3 Ganglioside [GM3]
GM1 Ganglioside [GM1]
Sulfatide [Sulfatide]
Sphingomyelin [SM]
Phosphatidylcholine [PC]
Alkylphosphatidylcholine [PC(O)]
Alkenylphosphatidylcholine [PC(P)]
Lysophosphatidylcholine [LPC]
Lysoalkylphosphatidylcholine [LPC(O)]
Lysoalkenylphosphatidylcholine [LPC(P)]
Phosphatidylethanolamine [PE]
Alkylphosphatidylethanolamine [PE(O)]
Alkenylphosphatidylethanolamine [PE(P)]
Lysophosphatidylethanolamine [LPE]
Lysoalkenylphosphatidylethanolamine [LPE(P)]
Phosphatidylinositol [PI]
Lysophosphatidylinositol [LPI]
Phosphatidylserine [PS]
Phosphatidylglycerol [PG]
Cholesteryl ester [CE]
Cholesterol [COH]
Dehydrocholesteryl ester [DE]
Acylcarnitine [AC]
Diacylglycerol [DG]
Triacylglycerol [TG]
Alkyldiacylglycerol [TG(O)]
Ubiquinone
Age
BMI
Sex
No. of APOE e4 alleles
HDL-C
Total triglycerides
Total cholesterol
Statin use
Omega-3 supplementation use

Dihydroceramide [dhCer]
Ceramide [Cer]
Monohexosylceramide [HexCer]
Dihexosylceramide [Hex2Cer]
Trihexosylceramide [Hex3Cer]
GM3 Ganglioside [GM3]
GM1 Ganglioside [GM1]
Sulfatide [Sulfatide]
Sphingomyelin [SM]
Phosphatidylcholine [PC]
Alkylphosphatidylcholine [PC(O)]
Alkenylphosphatidylcholine [PC(P)]
Lysophosphatidylcholine [LPC]
Lysoalkylphosphatidylcholine [LPC(O)]
Lysoalkenylphosphatidylcholine [LPC(P)]
Phosphatidylethanolamine [PE]
Alkylphosphatidylethanolamine [PE(O)]
Alkenylphosphatidylethanolamine [PE(P)]
Lysophosphatidylethanolamine [LPE]
Lysoalkenylphosphatidylethanolamine [LPE(P)]
Phosphatidylinositol [PI]
Lysophosphatidylinositol [LPI]
Phosphatidylserine [PS]
Phosphatidylglycerol [PG]
Cholesteryl ester [CE]
Cholesterol [COH]
Dehydrocholesteryl ester [DE]
Acylcarnitine [AC]
Diacylglycerol [DG]
Triacylglycerol [TG]
Alkyldiacylglycerol [TG(O)]
Ubiquinone
Age
BMI
Sex
No. of APOE e4 alleles
HDL-C
Total triglycerides
Total cholesterol
Statin use
Omega-3 supplementation use

Dihydroceramide [dhCer]
Ceramide [Cer]
Monohexosylceramide [HexCer]
Dihexosylceramide [Hex2Cer]
Trihexosylceramide [Hex3Cer]
GM3 ganglioside [GM3]
GM1 ganglioside [GM1]
Sulfatide [Sulfatide]
Sphingomyelin [SM]
Phosphatidylcholine [PC]
Alkylphosphatidylcholine [PC(O)]
Alkenylphosphatidylcholine [PC(P)]
Lysophosphatidylcholine [LPC]
Lysoalkylphosphatidylcholine [LPC(O)]
Lysoalkenylphosphatidylcholine [LPC(P)]
Phosphatidylethanolamine [PE]
Alkylphosphatidylethanolamine [PE(O)]
Alkenylphosphatidylethanolamine [PE(P)]
Lysophosphatidylethanolamine [LPE]
Lysoalkenylphosphatidylethanolamine [LPE(P)]
Phosphatidylinositol [PI]
Lysophosphatidylinositol [LPI]
Phosphatidylserine [PS]
Phosphatidylglycerol [PG]
Cholesteryl ester [CE]
Cholesterol [COH]
Dehydrocholesteryl ester [DE]
Acylcarnitine [AC]
Diacylglycerol [DG]
Triacylglycerol [TG]
Alkyldiacylglycerol [TG(O)]
Ubiquinone
Age
BMI
Sex
No. of APOE e4 alleles
HDL-C
Total triglycerides
Total cholesterol
Statin use
Omega-3 supplementation use

AIBL

Fig. 1 Characterisation of lipid isomeric species and the relationship of lipid classes and subclasses within the AIBL and ADNI cohorts.
a Characterisation of sphingomyelin isomers. Black trace corresponds to the chromatogram seen under normal conditions. Additional experimental
results in the green and blue traces used for identiﬁcation, corresponding to SM(d18:1/24:1) and SM(d18:2/24:0) respectively. b Characterisation of
glycerophospholipid isomers. Black trace corresponds to the chromatogram seen under normal conditions. Red trace is the same scan after sample
acid hydrolysis. c Spearman correlation of total lipid classes, subclasses and commonly reported clinical measures (bolded) for the AIBL baseline and
ADNI studies.
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2
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Fig. 2 Associations of lipid class totals with prevalent and incident Alzheimer’s disease. Forest plots of lipid class associations for a prevalent
Alzheimer’s disease (logistic regression, AIBL = 268 cases, 696 control, ADNI = 178 cases, 210 controls) and b incident Alzheimer’s disease (Cox
regression, AIBL = 68 cases, 714 controls, ADNI = 166 cases, 397 controls). Lipid classes are generated by the sum of each individual species measured in
each class. Regressions are adjusted for age, sex, BMI, total cholesterol, HDL-C, triglycerides, number of APOE4 alleles, statin use and omega-3
supplementation. AIBL was further adjusted for time points (only in logistic regression analysis) and site of blood collection. ADNI was further adjusted for
fasting status.
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Fig. 3 Associations of individual lipid species with prevalent Alzheimer’s disease. Forest plot outlining the logistic regression results of individual
species, between controls and prevalent AD in both the AIBL (blue n = 268 cases, 696 controls) and ADNI (red, n = 178 cases, 210 controls) cohorts with
the combined meta-analysis in the middle (green). P value was corrected for multiple comparison using approach by Benjamini and Hochberg. Covariates
include age, sex, BMI, total cholesterol, HDL-C, triglycerides, number of APOE4 alleles, statin use and omega-3 supplementation. Additional covariates for
AIBL include site of blood collection and time point while ADNI includes fasting status. Open circles, not signiﬁcant; closed dark circles, signiﬁcant after
FDR correction; coloured circles, top 20 associations ranked by p value.

71 species associated with incident AD in the meta-analysis
(Fig. 4 and Supplementary Table 4). One hundred and sixty-one
lipids had uncorrected p values < 0.05 and the majority of these
show the same direction of association as observed for AD
(Fig. 4a). These include individual species from the ether lipids,
sphingolipids, PE and TG classes. If we further adjust for individuals diagnosed with MCI, only three species remain signiﬁcant
after FDR correction, the sterol ester DE(18:1) and two plasmalogen species.
Multivariate modelling to identify lipids important in diagnosing prevalent or predicting future onset of AD. Due to the
feature selection process (selecting features based on frequency
incorporating into a multivariate model), we observed that
informatively prognostic lipids, but are otherwise highly correlated, would frequently be selected once in each model interchangeably, reducing their individual frequency count. We
utilised the correlation data to identify lipid clusters of highly
correlated species. The frequency of these clusters were then used
to rank (sum of individual incorporations), with the most
incorporated lipid in each cluster used as the representative for
the multivariate models (Supplementary Table 5).
In the disease classiﬁcation model where AIBL was the
discovery set and ADNI the replication, we observed a ﬁnal
concordance statistic (C-statistic) of 0.752 (0.747–0.757) through
the incorporation of 10 lipid species on top of the base model of
age, sex, BMI and APOE ε4 count (C-statistic of 0.731
[0.726–0.736]) with a Net Reclassiﬁcation Index (NRI) of 0.40
6

when tested on the ADNI study. For incident AD, we observed a
ﬁnal C-statistic of 0.675 (0.671–0.680), up from 0.644
(0.640–0.648) obtained from the base model alone (NRI of
0.40). The summary of results is presented in Table 2.
In the parallel analysis, where the ADNI was the discovery and
AIBL was the replication, the disease classiﬁcation model had a
ﬁnal C-statistic of 0.869 (0.866–0.871) through the incorporation
of 10 lipid species on top of the base model of age, sex, BMI and
APOE ε4 count (C-statistic of 0.820 [0.817–0.823]) with an NRI
of 0.84 when tested on the AIBL study. For prediction of future
disease onset, we observed a ﬁnal C-statistic of 0.733
(0.727–0.740), up from 0.716 (0.709–0.723) obtained from the
base model alone (NRI of 0.45). The summary of results is
presented in Table 2.
Discussion
Here we present our initial results from the lipidomic analysis of
the AIBL and ADNI cohorts. Our goal was to deﬁne the complex
associations between lipids and AD using our updated methodology by examining each cohort independently and subsequently combining them in a single meta-analysis. The
independent nature of these two studies allows for conﬁdence in
identifying lipids that are important in AD pathology.
The positive associations of PE, diacylglycerol and triacylglycerol with AD is similar to the associations seen with both prediabetes and type 2 diabetes23. These species tend to correlate
closely with clinically elevated levels of TGs and reduced HDL
cholesterol (dyslipidemia). Adjustment for these clinical lipid

NATURE COMMUNICATIONS | (2020)11:5698 | https://doi.org/10.1038/s41467-020-19473-7 | www.nature.com/naturecommunications

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19473-7

AIBL

Lipid class

Combined META
Cer(d18:1/24:1)

Cer(d18:1/24:1)

Cer(d19:1/18:0)

HexCer
Hex2Cer
Hex3Cer
GM3
GM1
Sulf atide
SM

ADNI
Sphingolipids

dhCer
Cer

Cer(d19:1/18:0)

Cer(d19:1/20:0)
Cer(d19:1/24:1)

Cer(d18:2/24:1)
Cer(d19:1/24:1)

GM3(d18:1/24:1)

PC
PC(18:2_20:5)

PC(O)

Glycerophospholipids

PC(P)

PC(P-16:0/22:6)
PE(18:0_22:5) (n3)

LPC
PE(16:0_16:0)

LPC(O)
LPC(P)
PE

PE(O-18:0/22:6)
PE(38:5) (a)

PE(O-16:0/22:6)

PE(O-18:0/20:4)

PE(O-18:1/22:6)

PE(O)
PE(P)

PE(15-MHDA_18:2)

PE(P-18:0/22:6)

PE(P-18:0/22:5) (n6)

LPE
LPE(P)
PI

PE(O-16:0/22:6)
PE(O-18:1/22:6)

PE(O-18:1/18:2)

LPE(18:0) [sn2]

PE(P-19:0/20:4) (b)
PE(P-17:0/22:6) (b)

PE(P-18:1/20:5) (a)
LPE(P-20:0)

LPE(18:0) [sn1]

PE(P-16:0/22:6)

LPI
PS
PG
CE

PE(P-16:0/22:6)

PE(P-18:1/22:6) (a)

DE(18:1)

DE(20:5)

TG
TG(O)
Ubiquinone

TG(50:3) [NL-16:1]

Neutral/other

DE(18:1)

DE(18:1)

COH
DE
AC
DG

PE(P-18:1/22:6) (a)

TG(O-52:2) [NL-16:0]

0.5
1
2
Hazard ratio (95% CI)
Uncorrected p > 0.05

Uncorrected p < 0.05

0.5
1
2
Hazard ratio (95% CI)
Corrected p > 0.05

Top 10 ranked by p-value*

Corrected p < 0.05

0.5
1
2
Hazard ratio (95% CI)
Uncorrected p > 0.05

Top 20 ranked by p-value

Uncorrected p < 0.05

Top 10 ranked by p-value

Fig. 4 Associations of individual lipid species with future onset Alzheimer’s disease. Forest plot outlining the Cox regression results of individual species,
between non-converters and future converters in both the AIBL (cyan n = 68 cases, 714 controls) and ADNI (orange, n = 166 cases, 397 controls) cohorts
with the combined meta-analysis in the middle (purple). P value was corrected for multiple comparison using approach by Benjamini and Hochberg.
Covariates include age (set as timescale), sex, BMI, total cholesterol, HDL-C, triglycerides, number of APOE4 alleles, statin use and omega-3
supplementation. Open circles, not signiﬁcant; closed dark circles, uncorrected p value; coloured squares, top 10/20 associations ranked by p value.

measures resulted in a loss of signiﬁcance at the class level;
however, multiple species within these classes retained a signiﬁcant association with AD (Fig. 3). Interestingly, we observe
mostly monounsaturated acyl species driving the associations
within these classes. Several studies have highlighted the association of dyslipidemia and insulin resistance with the risk of both
vascular dementia and AD24,25. It may also be possible that the
positive association observed with the PE class is a compensatory
increase due to the decreases of PE(P) species, a phenomenon
that has been reported in plasmalogen-deﬁcient mice26.
A key difference between plasmalogens and non-plasmalogen
ether lipids is the vinyl-ether bond in the sn1 position, which is
susceptible to oxidation27. Little of the recently reported metabolomic literature with respect to AD has differentiated these two
classes5,14–17. To further complicate this issue, studies which have
obtained data from unit resolution mass spectrometers were
unable to differentiate these species from isobaric species (odd
numbered di-acyl lipids), unless extensive chromatography has
also been employed. For example, PC(35:2) has a mass difference
of 0.036 Da from PC(O-36:2) and PC(P-36:1), of which the latter
two share identical masses (isomeric). When measured on a unitresolution instrument without chromatography5, these all contribute to the same signal. This can raise issues in instances where
these species associate differently with the outcome. This is
exempliﬁed in the inverse relationship of odd-chain and ether
lipids with AD (Supplementary Table 3), highlighting the
importance of differentiating these species.
It has been proposed that plasmalogens act as endogenous
antioxidants through their vinyl-ether bond and that increased

oxidative stress may explain the lower levels observed in AD
patients28. However, both plasmalogen and non-plasmalogen
ether species showed similar associations with AD. Alkyl ether
lipids are less susceptible to oxidation compared to their plasmenyl counterparts, suggesting associations with AD more likely
reﬂect changes to the biosynthetic pathway. In support of this,
Grimm et al.29 reported dysregulation of the peroxisomal enzymes
relating to plasmalogen synthesis in AD. Plasmalogens have been
reported to be involved in several physiological functions
including maintenance of lipid raft domains30 which are important for secretase function, responsible for Aβ production31,
cholesterol efﬂux32 and cellular survival33. Importantly, peripheral
intravenous administration of plasmalogens has been shown to
inhibit Aβ accumulation in a study involving neuroinﬂammation34. Impairment to the synthetic pathway of ether lipids may
have deleterious downstream effects, and, in fact, these species
have been proposed as potential therapeutic compounds35.
We have observed diverse associations of speciﬁc n-acylated
ceramides with AD: positive associations were observed with
species containing 18:0, 20:0 and 24:1 fatty acids, whereas negative or neutral associations were observed for species containing
22:0, 24:0 and 26:0 fatty acids, irrespective of the sphingoid base.
In contrast, signiﬁcant associations of sphingolipids with incident
AD were only observed for species containing nervonic acid
(24:1). This effect was much stronger in the AIBL study, while
ADNI exhibited similar trends but were not signiﬁcant after FDR
correction. Despite this, the meta-analysis of sphingolipid associations resulted in much more power than utilising the AIBL
study alone (Supplementary Table 3).
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model comprises GM3(d18:1/24:1), PC(O-32:2), PC(15-MHDA_18:1), AC(13:0), PC(P-18:0/22:5), CE(17:0), PC(O-38:5), Cer(d18:2/26:0), PC(P-16:0/18:2) and PC(P-16:0/20:4).
model comprises PE(O-36:5), SM(d18:2/18:1), PC(O-40:7) (b), SM(43:1), PE(16:0_18:3) (b), CE(24:5), LPC(20:2) [sn1], PS(38:4), GM3(d18:1/20:0) and GM3(d18:1/24:0).
model comprises DE(18:1), Cer(d18:1/24:1), LPE(18:0) [sn1], Cer(d19:1/24:1) and SM(41:0).
model comprises DE(18:1), TG(O-52:2) [NL-16:0], PE(16:0_20:3), Cer(d19:1/18:0) and Hex3Cer(d18:1/22:0).

0.731 (0.726–0.736)
0.752 (0.747–0.757)
0.820 (0.817–0.823)
0.869 (0.866–0.871)
0.644 (0.640–0.648)
0.675 (0.671–0.680)
0.716 (0.709–0.723)
0.733 (0.727–0.740)
Age + Sex + BMI + APOE
Age + Sex + BMI + APOE + 10 lipidsa
Age + Sex + BMI + APOE
Age + Sex + BMI + APOE + 10 lipidsb
Age + Sex + BMI + APOE
Age + Sex + BMI + APOE + 5 lipidsc
Age + Sex + BMI + APOE
Age + Sex + BMI + APOE + 5 lipidsd
Future onset of AD

aLipid
bLipid
cLipid
dLipid

C-statistic 95% CI
Model

–
0.40 (0.38 – 0.42)
–
0.84 (0.82–0.85)
–
0.25 (0.23–0.27)
–
0.45 (0.41–0.48)

–
0.19 (0.17–0.20)
–
0.44 (0.42–0.45)
–
0.05 (0.04–0.07)
–
0.17 (0.14–0.21)
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Discovery: AIBL
Replication: ADNI
Discovery: ADNI
Replication: AIBL
Discovery: AIBL
Replication: ADNI
Discovery: ADNI
Replication: AIBL
Diagnosis of AD

Table 2 Summary of modelling statistics.

Net Reclassiﬁcation Index (total)

Net Reclassiﬁcation Index (event)

ARTICLE

Synthesis of 24:1 is likely through elongation of 18:1 which
itself is synthesised through unsaturation via stearoyl-CoA
desaturase 1 (SCD-1). Interestingly, increased SCD-1 activity
has previously been associated with AD36, and this may be
contributing to the increased abundance of these monounsaturated lipid species. We observed similar positive associations with 18:1 relative to 18:0 in many of our measured lipid
species, particularly species with a single fatty acid (e.g. LPC and
CE species, Supplementary Table 3). Interestingly SCD-1 is
associated with insulin resistance and adiposity, and mouse
experiments have shown that disrupting SCD-1 function can
potentially reduce body adiposity and improve insulin sensitivity37. This is relevant as obesity, insulin resistance and diabetes
type II are all likely linked to increased risk of AD38
Speciﬁc ceramide synthases are responsible for the n-acylation
of ceramide species, in particular, ceramide synthase 2 (20:0 to
26:0) and 3 (22:0 to 26:0)39. Decreases in the activity of ceramide
synthase 2 (CerS2) have been observed in AD, early in pathogenesis40. Thus, the negative association of Cer(22:0), Cer(24:0)
and Cer(26:0) may be driven by decreases of CerS2, while the
positive association of Cer(24:1) driven by SCD-1 cancels out the
negative association observed with CerS2, which would, on its
own, be expected to result in decreased levels of this species.
Gangliosides are a group of sphingolipids with oligosaccharide
groups linked to the sphingoid base. GM3 gangliosides, the most
abundant circulating ganglioside class, is positively associated
with AD. Gangliosides have been reported to accelerate Aβ
aggregation, leading to deposition in the brain41. While the
mechanism leading to increased circulating gangliosides is currently not known, gangliosides are not commonly measured, and
thus far no other reports have described an association between
circulating GM3 gangliosides and AD.
The demographic and study design differences between the
AIBL and ADNI cohorts presented a unique opportunity to
validate some of the lipid markers in this study. Despite the
geological differences with the two studies, the cross-sectional
associations identify fairly similar associations and patterns
within the lipidome and disease outcome. However, one challenge
was the study design differences, where the distribution of control, MCI and AD cases were quite different (approximately
7:1:2.5 for AIBL and 1:2:1 for ADNI) which resulted in some
differences of important variables in the multivariate modelling,
thus requiring retraining of the coefﬁcients in the replication set
despite normalisation. Nonetheless, we were able to identify
several lipids that appear to be key in identifying individuals who
have, or are at, risk of developing AD. These lipids highlight
unique features that provide information on top of easily
obtained anthropometric (age, sex, BMI) and biochemical features (APOE ε4 alleles). While we were able to test and validate
these models across the two cohorts, ultimately a population
study will be required to fully assess model performance.
While our lipidomic methodology offers a broad coverage of
the lipidome, in the absence of stable isotope standards for each
of the 569 lipid species, lipidomics will not provide exact quantiﬁcation. We include a single internal standard per lipid class
to provide quantitative data, while acknowledging that differential
response factors will lead to slight offsets of the calculated
concentration relative to their true concentration. However, this
does not impact the association analyses performed in this study
nor the multivariate modelling to predict prevalent and
incident AD.
Cross-sectional studies have some inherent limitations. We
observed strong associations between 218 plasma lipid species
and AD. However, dysregulation of the lipidome can arise from
sources other than the disease pathology (reverse causation), for
example, dietary and activity changes arising as AD progresses.
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To address this, we were also able to perform association studies
with incident AD where we identiﬁed similar, albeit weaker,
associations with the majority of the same lipid species.
The AIBL and ADNI cohorts represent two powerful studies to
characterise AD and the combination provides the opportunity to
validate ﬁndings across studies. However, these cohorts were
selected to be high risk for AD and so traditional risk factors,
including age and APOE genotype, are stronger predictors than
in an unselected population. As a consequence, these cohorts
likely underestimate the performance of risk models for incident
AD and further studies on balanced population cohorts will be
required.
To conclude, we have performed one of the most comprehensive lipidomic analysis of AD to date by utilising two large,
independent clinical studies in AD. We have provided a holistic
picture of lipid dysregulation associated with both prevalent and
incident AD. Our plasma lipid dataset expands the scientiﬁc literature by providing greater resolution and allowing ﬁne-granular
analysis of the lipidome. Here we have highlighted speciﬁc
changes to the ether lipid pathway, where plasmalogens are not
the only drivers of ether lipid associations. Class-wide and
species-speciﬁc changes highlight the necessity of a broad and
detailed assay to capture these minute differences in the lipidome.
We have demonstrated the potential of plasma lipids as the
markers to improve assessment of prevalent and incident AD,
highlighting the importance of these small molecules in both
disease prognostics and understanding the metabolic changes
occurring with the disease.
Methods
Participants. The AIBL study recruited 1112 individuals over the age of 60 years
into a longitudinal study42. At baseline, this comprised 768 cognitively normal, 133
with mild cognitive impairment and 211 with AD. Time points for blood/data
collection were every 18 months from baseline. Detailed description of the participants was adapted from Ellis et al.42. We analysed all available fasted plasma
samples (4106) from baseline up to the ﬁfth time point. After ﬁltering for missing
values and problematic samples, the breakdown of sample numbers used in statistical analysis is presented in Table 1. In total, there were 1073, 963, 731, 702 and
564 samples at baseline, and follow-up times 1–4, respectively. While there were
decreasing number of samples at successive time points, this was not completely
driven by attrition, as some were missing owing to low sample material or were
unobtainable at the start of the lipidomics study.
The ADNI1 study started in 2004 and recruited about 800 individuals at
baseline. The initial goal was to recruit 200 participants with mild AD and 200
controls as well as 400 participants with MCI. Study data analysed here were
obtained from the ADNI database, which is freely available online (http://adni.loni.
usc.edu/). We utilised serum samples from the ADNI1 baseline cohort and followup data from the 6-, 12-, 18-, 24- and 36-month recalls for incident AD analysis.
Classiﬁcation of disease state. Classiﬁcation of MCI and AD in the AIBL cohort
has been described extensively in previous publications42. Clinical criteria used to
determine disease status included Mini Mental State Examination score of less than
28, failure on the Logical Memory test (in accordance with the ADNI criteria),
other evidence of possible signiﬁcant cognitive difﬁculty on neuropsychological
testing, a Clinical Dementia Rating score of 0.5 or greater, a medical history suggestive of the presence of illnesses likely to impair cognitive function, an informant
or personal history suggestive of impaired cognitive function, or who were consuming medications or other substances that could affect cognition42. A more indepth description of the ADNI cohort diagnostic criteria is reported elsewhere43;
brieﬂy, AD dementia diagnosis was established using NINDS‐ADRDA criteria for
probable AD. Classiﬁcation as MCI followed the Petersen et al.44 criteria described
previously.
Lipid extraction and liquid chromatography mass spectrometry. Lipids were
extracted from 10 μl plasma (AIBL) or serum (ADNI), with the addition of an
internal standard mix (Supplementary Table 2), using the single-phase butanol/
methanol extraction method45. In brief, 10 μl of samples were mixed with 100 μl of
1:1 butanol:methanol containing the internal standards22, the samples were vortexed, sonicated on a sonicator bath and centrifuged (13,000 × g, 10 min). The
supernatants were transferred into glass vials and stored at −80 °C. On average,
486 samples were extracted per day. Prior to mass spectrometry analysis, samples
were thawed for 1 h at room temperature, vortexed and sonicated on the sonicator
bath for 15 min and left to sit at 25 °C for 2 h prior to analysis.
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Analysis of plasma extracts was performed on an Agilent 6490 QQQ mass
spectrometer with an Agilent 1290 series HPLC system. Mass spectrometry settings
and transitions for each lipid class are shown in Supplementary Table 2.
Mass spectrometer running conditions were gas temperature 150 °C, gas ﬂow
rate 17 l/min, nebulizer gas pressure 20 psi, sheath gas temperature 200 °C,
capillary voltage 3500 V and sheath gas ﬂow 10 l/min. Isolation widths for Q1 and
Q3 were set to “unit” resolution (0.7 amu). The Agilent 1290 HPLC conditions
were as follows: The composition of running solvents A and B comprised 50:30:20
and 1:9:90 water, acetonitrile and isopropanol, respectively. A ZORBAX eclipse
plus C18 (2.1 × 100 mm 1.8 mm, Agilent) column was used. Solvents were run at a
ﬂow rate of 0.4 ml/min with the column compartment temperature set to 60 °C.
The solvent gradient was as follows: starting at 10% B and increasing to 45% B over
2.7 min (while diverting to waste for the ﬁrst minute), then to 53% B over 0.1 min,
to 65% B over 6.2 min, to 89% B over 0.1 min, to 92% B over 1.9 min and ﬁnally to
100% over 0.1 min. The solvent was then held at 100% B for 0.8 min and returned
to 10% B over 0.1 min (a combined total of 12 min). The column was reequilibrated in 10% B at an adjusted ﬂow rate (0.4 ml/min for 0.9 min, then
0.6 ml/min for 1 min, then back to 0.4 ml/min for 0.9 min) prior to the next
injection.
Additional experiments using pooled samples were utilised under varying
conditions to get acyl composition data. To obtain further structural detail of
isomeric and isobaric lipid species under the presented chromatographic
conditions, we performed additional fragmentation experiments using pooled
samples22. The additional experiments to characterise the lipid species include acid
hydrolysis, which selectively depletes plasmalogens leaving non-plasmalogen ether
species intact, fragmentation in the presence of lithium ions in positive ionisation
mode and fragmentation in negative ionisation mode, both of which yield
characteristic product ions for structural elucidation under our reported analytical
conditions22.

Data integration, batch alignment and statistical analysis. Peak area of the lipid
species was related to the internal standards to generate concentration data. To
remove technical batch variation, the lipid data in each analytical batch
(approximately 486 samples a batch) were aligned by using the median value of
each lipid of the plasma quality control samples. As most lipid species were
positively skewed, ﬁnal lipid concentrations were log10 transformed prior to statistical analysis. Lipid class totals were generated by summing the individual species
within each class.
All statistical analyses were performed in the R statistical platform (version 3.4.1+).
For logistic and Cox regression, lipid data were scaled by the standard deviation and
mean centred within each cohort. When examining associations with prevalent disease,
we excluded MCI individuals from the analysis in both studies to provide a clean
distinction between disease and non-disease. Furthermore, to maximise the number of
AD samples in the prevalent disease analysis, we utilised the last acquired sample for
each participants and have added covariates corresponding to each time point to adjust
for possible confounding effects.
For examining incident disease analysis, we utilised the baseline samples only.
This analysis included healthy and MCI individuals. For both analyses, the metaanalysis was performed using the “meta” package in R and was performed using a
ﬁxed effects model.
Correlation analysis was performed using Spearman correlation, with
hierarchical clustering of co-linear lipids (complete distance method) followed by
tree cutting using the Dynamic cut R package (hybrid method), resulting in 150
and 148 clusters for the AIBL and ADNI lipid data, respectively.
Common covariates utilised in statistical analysis include age, sex, BMI, HDL
cholesterol, total cholesterol, clinical TGs, statin use and omega-3 supplementation.
FDR correction was performed using the method of Benjamini and Hochberg46
using the nominal p values from each univariate analysis (569 comparisons for
individual lipid species and 32 comparisons for lipid classes). Meta-analysis to
combine the results between the two cohorts was conducted using an inversevariance weighted averaged ﬁxed effect meta-analysis, with similar FDR corrections
applied to the nominal p values. For modelling, each cohort was Z-scored
independently.

Multivariate modelling of AD. We leveraged the availability of two independent
cohorts to train and test different lipid models to diagnose prevalent disease
(logistic models) and identify individuals at risk of future AD onset (Cox models).
We used one cohort to deﬁne a set of features (discovery) for a multivariate model
(common clinical variables + multiple lipid species) and used the second cohort to
test these features for their predictive performance (replication). We then repeated
this process switching the cohorts around.
With the AIBL cohort, we used a 2:1 age–sex-matched baseline subset
(Supplementary Table 1) due to the low incidence of conversion and the large age
difference between converters and non-converters within the cohort. Similarly, we
did not adjust for MCI in these models to better allow the predictive performance
of the lipidomic markers to be assessed. Due to the different population
distribution and characteristics of the two cohorts (AIBL and ADNI) we retrained
the model (using the selected features) on the replication cohort. This was also
done in a cross-validated framework to avoid overﬁtting.
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To deﬁne a feature list in the discovery cohort, we generated a series of models
using forward stepwise regression, adding lipid species to the existing covariates (to
a maximum of 5 lipids for the Cox model and 10 for the logistic model), while
minimising the Akaike Information Criterion, within a 10-fold cross validation
framework.
We rationalised that a stepwise approach would help us to maximise model
performance while incorporating a minimum number of lipid species into the
model, producing a simpler model to minimise the potential of overﬁtting. We
used the frequency of incorporation into the training models, after accounting for
clustering of co-linear lipids, to deﬁne a set of features that were subsequently
validated in the replication cohort.
The need to consider highly correlated lipids within clusters in our selection
process was due to the tendency of these lipid species to be selected in different
cross-validation folds, and thus reduce the ranking of these correlated lipid species
despite being strong predictors of AD. By considering these correlated lipids within
clusters, ranking the clusters and selecting only the top ranked lipid within each
cluster, we optimised the ranking of the most powerful predictors while avoiding
the selection of highly correlated lipid species.
For replication, the features selected from the discovery cohort were modelled
in the replication cohort, also within a 10-fold cross-validation framework. The Cstatistic and NRI were calculated after 200 repeats from the replication results. This
process was repeated such that AIBL and ADNI were utilised as both discovery and
replication sets.
Naming convention of lipid species. The lipid naming convention used here
follows the guidelines established by the Lipid Maps Consortium and the shorthand notation established by Liebisch et al.47–49. We identiﬁed several species of
interest that are not structurally resolved. These species separated chromatographically but incompletely characterised were labelled with an (a) or (b) to
differentiate them, for example PC(P-17:0/20:4) (a) and PC(P-17:0/20:4) (b) where
(a) and (b) represent the elution order. Separated isoforms that contain a 16:0
methyl branched fatty acid are presented as MHDA (methylhexadecanoic acid).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
Data to support these ﬁndings are available online and upon request. The entire ADNI
lipidomic and clinical characteristic data are available online (adni.loni.usc.edu,
speciﬁcally, ADMC Lipidomics Meikle Lab Baseline Data Matrix [ADNI1]) and the
remaining data (AIBL) used in this study are available from both the corresponding
authors and online at https://aibl.csiro.au upon reasonable request. Source data are
provided with this paper.
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